Figure 1. T cell-derived CD70 inhibits inflammatory bowel disease (IBD).

(A) Naïve RAG1^−/− mice in the C57BL/6 strain background were injected with 1×10⁶ CD4⁺CD25⁻ T cells purified from C57BL/6 WT or CD70^−/− mice. Body weight was monitored after adoptive transfer. Representative weight data from 1 out of 3 independent experiments were shown as mean ± SD (n=4 per group), with statistical significance determined by two-way ANNOVA. (B) Kaplan-Meier survival data were summarized by combining 3 independent experiments (n=10–11 per group), with statistical significance determined by Log-rank test. (C-D) Naïve RAG1^−/− mice were injected with 1×10⁶ CD4⁺CD25⁻ T cells purified from C57BL/6 WT mice, and then treated from day 1 with 100ug of either CD70 antibody (FR70) or IgG control twice weekly for the duration of the experiment. (C) Body weight was shown as mean ± SD, with statistical significance determined by two-way ANNOVA. (D) Kaplan-Meier survival curves were shown with statistical significance determined using Log-rank test. (E-F) RAG1^−/− host mice were sacrificed on days 17, 36 and 66. A blinded pathologist scored large (E) and small (F) intestines based on disease criteria outline in the Experimental Procedures. Summary scores combined from 3 independent experiments were shown, with statistical significance determined by unpaired student t test. (G) Representative histopathological images were shown for large intestine samples harvested from RAG1^−/− host mice at day 36 after adoptive transfer.